Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur, and the underlying cause in 70% of people with dementia. Dementia, which is not a specific disease but an overall term that describes a group of symptoms, is characterized by a decline in memory, thinking, [...]
Kicked off in December 2020, a third stream of the Value of Treatment project on Transversal Topics is officially underway over a three-year period from 2021 to 2023. A case study on chronic pain has begun and soon a case study on sleep and wake disorders is to follow, potentially among others. The group [...]
On 8 June 2021, EBC hosted a virtual Synthesis Meeting for the Value of Treatment 2 case study working groups to present their preliminary findings. The Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council (EBC). EBC conceptualized in 2015 the Value [...]
EBC is happy to recognise and support International Phenylketonuria (PKU) Day, which takes place annually on 28 June — the birthday of two stalwarts of PKU, Robert Guthrie (1916-1995) and Horst Bickel (1918-2000). The ongoing 2019-2021 Value of Treatment (VOT) project for Brain Disorders and its recent synthesis meeting on 8 June 2021 aimed to [...]
We are excited to announce that after one year of digital sessions, the Brain Innovation Days will take place in person on 12-13 October 2021 in Brussels, Belgium. Under the overarching theme, United for Brain Innovation, the Brain Innovation Days will bring together key opinion leaders and stakeholders from the ever-growing brain innovation ecosystem to create [...]
The Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council (EBC). EBC conceptualized the Value of Treatment research framework to address the increasing burden of brain disorders – both neurological and mental alike. Budgetary restrictions across the EU are threatening the sustainability [...]
On the occasion of the approaching World Multiple Sclerosis Day (30 May 2021), the European Brain Council is excited to announce the release of its new policy paper, "RETHINKING MS in times of COVID-19". This new paper is part of the main report "RETHINKING MS in Europe", a research-driven project offering tangible policy changes [...]
The European Brain Council is pleased to invite you to register for the digital event "Patient safety and informed consent: The importance of good off-label use practices" to be held virtually on 17 June 2021 at 14:30 - 16:00CET. The event is co-organised with EUCOPE. In 2016, the Declaration for Good Off-Label Use Practice was launched, supported [...]
There is consensus among stakeholders that patient engagement at different points of the medicines lifecycle is critical to fostering patient access to innovative therapeutic solutions, and delivering better health outcomes for patients. IMI PARADIGM, a public private consortium consisting of patients, academia, industry, HTA bodies and regulators, developed a toolkit to make patient engagement [...]
The European Brain Council is pleased to invite you to join us for the upcoming Value of Treatment for Brain Disorders Research Project “Case studies on Rare Diseases and Mental Disorders” Virtual Synthesis Meeting to be held on 8 June 2021 at 13:00-17:30. The Value of Treatment (VOT) is a health economics and outcomes research project addressing all brain disorders, conceptualized in 2015 by the [...]
